Klotho Neurosciences (KLTO)announced that its Letter of Intent, or LoI, with Turn Biotechnologies was allowed to expire by the parties. Following careful evaluation, Klotho’s Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and shareholders.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences to acquire select assets from Turn Biotechnologies
- Klotho Neurosciences Faces Nasdaq Delisting Notice
- Klotho Neurosciences Delays Quarterly Report Filing
- Klotho Neurosciences Partners with AAVnerGene for Gene Therapy
- Klotho Neurosciences signs KLTO-202 manufacturing, development agreement